VCRE
Vicore Pharma Holding AB
There isn't enough reported data to score VCRE yet.
VCRE Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Under pressure | |
| Unavailable |
VCRE's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
VCRE PE Valuation
VCRE has no meaningful PE right now: it lost money over the past year.
VCRE Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong decline | |
| -- | |
| Limited | |
| High |
Analysts expect VCRE's revenue to decline, with its earnings and profitability holding steady.
VCRE Earnings Per Share
VCRE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $22.9K | -87% |
| Q1 2026 | $60.5K | -33% |
| Q4 2025 | $42.1K | -9.2% |
| Q1 2025 | $89.6K | -91% |
VCRE's revenue has slid since its 2024 peak: $22,939 last quarter, down 87% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -6783% | -416 points |
| Q1 2026 | -20572% | -10309 points |
| Q4 2025 | -31911% | -30067 points |
| Q3 2025 | -15258% | N/A |
| Q2 2025 | -6367% | N/A |
| Q1 2025 | -10263% | -8522 points |
| Q4 2024 | -1844% | N/A |
| Q1 2024 | -1741% | N/A |
VCRE's operating margin was −6783% last quarter, down 416 points from the same quarter a year ago.
VCRE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$1.6M | +$9.1M |
| Q1 2026 | -$11.8M | -$3.2M |
| Q4 2025 | -$8.2M | -$3M |
| Q3 2025 | -$1.1M | +$7.6M |
| Q2 2025 | -$10.7M | -$10.2M |
| Q1 2025 | -$8.7M | -4083% |
| Q4 2024 | -$5.1M | -$4.5M |
| Q3 2024 | -$8.7M | -$5.1M |
VCRE has burned cash in almost every quarter: −$23M over the past year, against −$33M the year before.
VCRE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.5% | -144K shares |
| 1 year | +19% | +4.6M shares |
| 3 years | +290% | +20.8M shares |
VCRE has 28M diluted shares, up 19% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
VCRE hasn't bought back shares in the past year.
VCRE Net Leverage
VCRE's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
VCRE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 20.0 | Oversold |
| Stochastic | 47.8 | Neutral |
VCRE's weekly RSI is 20 (oversold) and its Stochastic is 48 (neutral).
VCRE PE vs Healthcare Sector
VCRE has no meaningful PE right now: it lost money over the past year.
VCRE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $9.69 | 13% above |
VCRE is in an uptrend: it's above all one of its weekly moving averages, and 13% above its 8-week average.
VCRE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2026 YTD | $13.8 | $11.0 | -20% |
It's down 20% so far in 2026.